Literature DB >> 21671475

An American founder mutation in MLH1.

Jerneja Tomsic1, Sandya Liyanarachchi, Heather Hampel, Monika Morak, Brittany C Thomas, Victoria M Raymond, Anu Chittenden, Hans K Schackert, Stephen B Gruber, Sapna Syngal, Alessandra Viel, Elke Holinski-Feder, Stephen N Thibodeau, Albert de la Chapelle.   

Abstract

Mutations in the mismatch repair genes cause Lynch syndrome (LS), conferring high risk of colorectal, endometrial and some other cancers. After the same splice site mutation in the MLH1 gene (c.589-2A>G) had been observed in four ostensibly unrelated American families with typical LS cancers, its occurrence in comprehensive series of LS cases (Mayo Clinic, Germany and Italy) was determined. It occurred in 10 out of 995 LS mutation carriers (1.0%) diagnosed in the Mayo Clinic diagnostic laboratory. It did not occur among 1,803 cases tested for MLH1 mutations by the German HNPCC consortium, while it occurred in three probands and an additional five family members diagnosed in Italy. In the U.S., the splice site mutation occurs on a large (∼4.8 Mb) shared haplotype that also harbors the variant c.2146G>A, which predicts a missense change in codon 716 referred to here as V716M. In Italy, it occurs on a different, shorter shared haplotype (∼2.2 Mb) that does not carry V716M. The V716M variant was found to be present by itself in the U.S., German and Italian populations with individuals sharing a common haplotype of 280 kb, allowing us to calculate that the variant arose around 5,600 years ago (225 generations; 95% confidence interval 183-272). The splice site mutation in America arose or was introduced some 450 years ago (18 generations; 95% confidence interval 14-23); it accounts for 1.0% all LS in the Unites States and can be readily screened for.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671475      PMCID: PMC3266960          DOI: 10.1002/ijc.26233

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Population growth of human Y chromosomes: a study of Y chromosome microsatellites.

Authors:  J K Pritchard; M T Seielstad; A Perez-Lezaun; M W Feldman
Journal:  Mol Biol Evol       Date:  1999-12       Impact factor: 16.240

2.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

3.  Estimating the age of rare disease mutations: the example of Triple-A syndrome.

Authors:  E Genin; A Tullio-Pelet; F Begeot; S Lyonnet; L Abel
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

4.  Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer.

Authors:  A L Moisio; P Sistonen; J Weissenbach; A de la Chapelle; P Peltomäki
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

5.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.

Authors:  Heather Hampel; Wendy Frankel; Jenny Panescu; Janet Lockman; Kaisa Sotamaa; Daniel Fix; Ilene Comeras; Jennifer La Jeunesse; Hidewaki Nakagawa; Judith A Westman; Thomas W Prior; Mark Clendenning; Pamela Penzone; Janet Lombardi; Patti Dunn; David E Cohn; Larry Copeland; Lynne Eaton; Jeffrey Fowler; George Lewandowski; Luis Vaccarello; Jeffrey Bell; Gary Reid; Albert de la Chapelle
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

6.  Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing.

Authors:  S Syngal; E A Fox; C Li; M Dovidio; C Eng; R D Kolodner; J E Garber
Journal:  JAMA       Date:  1999-07-21       Impact factor: 56.272

7.  A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.

Authors:  Mark Drost; Jos e B M Zonneveld; Linda van Dijk; Hans Morreau; Carli M Tops; Hans F A Vasen; Juul T Wijnen; Niels de Wind
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

8.  Recurrent germline mutation in MSH2 arises frequently de novo.

Authors:  D C Desai; J C Lockman; R B Chadwick; X Gao; A Percesepe; D G Evans; M Miyaki; S T Yuen; P Radice; E R Maher; F A Wright; A de La Chapelle
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

9.  Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers.

Authors:  L D Kowalski; D G Mutch; T J Herzog; J S Rader; P J Goodfellow
Journal:  Genes Chromosomes Cancer       Date:  1997-03       Impact factor: 5.006

10.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.

Authors:  Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde
Journal:  Am J Hum Genet       Date:  2003-03-25       Impact factor: 11.025

View more
  8 in total

1.  Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.

Authors:  Monika Morak; Verena Steinke-Lange; Trisari Massdorf; Anna Benet-Pages; Melanie Locher; Andreas Laner; Katrin Kayser; Stefan Aretz; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

2.  Genetic genealogy uncovers a founder deletion mutation in the cerebral cavernous malformations 2 gene.

Authors:  Carol J Gallione; Matthew R Detter; Adrienne Sheline; Henrietta M Christmas; Cornelia Lee; Douglas A Marchuk
Journal:  Hum Genet       Date:  2022-04-30       Impact factor: 5.881

3.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

4.  Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.

Authors:  Christina Therkildsen; Anna Isinger-Ekstrand; Steen Ladelund; Anja Nissen; Eva Rambech; Inge Bernstein; Mef Nilbert
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

5.  Recurrent and founder mutations in the PMS2 gene.

Authors:  J Tomsic; L Senter; S Liyanarachchi; M Clendenning; C P Vaughn; M A Jenkins; J L Hopper; J Young; W Samowitz; A de la Chapelle
Journal:  Clin Genet       Date:  2012-06-04       Impact factor: 4.438

6.  Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome.

Authors:  Annette Y Sunga; Charité Ricker; Carin R Espenschied; Danielle Castillo; Marilena Melas; Josef Herzog; Sarah Bannon; Marcia Cruz-Correa; Patrick Lynch; Ilana Solomon; Stephen B Gruber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2017-02-09

7.  Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.

Authors:  Jenny von Salomé; Tao Liu; Markku Keihäs; Moni Morak; Elke Holinski-Feder; Ian R Berry; Jukka S Moilanen; Stéphanie Baert-Desurmont; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

8.  A Novel Germline MLH1 In-Frame Deletion in a Slovenian Lynch Syndrome Family Associated with Uncommon Isolated PMS2 Loss in Tumor Tissue.

Authors:  Gašper Klančar; Ana Blatnik; Vita Šetrajčič Dragoš; Vesna Vogrič; Vida Stegel; Olga Blatnik; Primož Drev; Barbara Gazič; Mateja Krajc; Srdjan Novaković
Journal:  Genes (Basel)       Date:  2020-03-18       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.